J Lung Cancer.  2008 Jun;7(1):25-28. 10.6058/jlc.2008.7.1.25.

Impact of Oral Administration of UFT for Postoperative Stage I Non-Small Cell Lung Cancer

• Kim JB
• Park CK

• KMID: 2200069
• DOI: http://doi.org/10.6058/jlc.2008.7.1.25

Abstract

PURPOSE : To determine the etiology of distant metastasis that was a major factor in the death of a patient with early stage non-small cell lung cancer (NSCLC). Recent studies have suggested that UFT may be effective adjuvant chemotherapy for completely resected early stage NSCLC. This study was designed to clarify the feasibility of UFT adjuvant chemotherapy in early stage NSCLC.
MATERIALS AND METHODS
: We administered UFT adjuvant chemotherapy for 24 months to patients with completely resected stage I NSCLC from January 2003 to January 2007 and compared the results in patients who did not receive UFT. The control group was recruited between March 1992 and December 2003. The UFT group was followed until death or the study cut-off date (20 October 2007). The control group was followed until September 2004.
RESULTS
: The UFT group was comprised of 28 patients. In the UFT group, 18 patients had adenocarcinomas and 10 patients had squamous cell carcinomas. The control group was comprised of 91 patients. In the control group, 34 patients had adenocarcinomas and 57 patients had squamous cell carcinomas. Thirty-five patients in the control group recurred (38.5%) and 9 patients in the UFT group (32%) recurred.
CONCLUSION
: The oral administration of UFT adjuvant chemotherapy was well-tolerated long-term without severe complications. Especially in stage I NSCLC, there was an improvement in the survival rate in patients treated with UFT, even though there was no statistical difference compared to the control group. Additional studies will be necessary to demonstrate the clinical significance of UFT treatment in early NSCLC

Keyword

Lung cancer; Adjuvant therapy

MeSH Terms

Adenocarcinoma
Administration, Oral
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Chemotherapy, Adjuvant
Humans
Lung Neoplasms
Neoplasm Metastasis
Survival Rate

Reference

References

1. Tsuboi M, Ohira T, Saji H, et al. The present status of postoperative adjuvant chemotherapy for completely resected nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg. 2007; 13:73–77.

2. Martini N. Surgical treatment of nonsmall cell lung cancer by stage. Semin Surg Oncol. 1990; 6:248–254.

3. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995; 109:120–129.

4. Socinski M, Detterbeck F, Rosenman J. Adjuvant therapy of resected nonsmall cell lung cancer. Detterbaeck F, Rivera M, Socinski M, Rosenman J, editors. Diagnosis and Treatment of Lung Cancer: An Evidence-based Guide for the Practicing Clinician. Philadelphia, PA: W.B. Saunders Company;2001. p. 206–219.

5. Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected nonsmall cell lung cancers in Japan: a Japanese Lung Cancer Registry Study. Lung Cancer. 2005; 50:227–234.

6. Matthews MJ, Kanhouwa S, Pickren J, et al. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 3. 1973; 4:63–68.

7. Non-small Cell Lung Collaborative Group. Chemotherapy in nonsmall cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomized trials. BMJ. 1995; 311:899–909.

8. Logan DM, Lochrin CA, Darling G, et al. Adjuvant radiotherapy and chemotherapy for stage II or IIIA nonsmall cell lung cancer after complete resection. Cancer Prevent Control. 1997; 1:366–378.

9. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA nonsmall-cell lung cancer. N Engl J Med. 2000; 343:1217–1222.

10. Tada H, Tsuchiya R, Ichinose Y, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected p-N2 nonsmall cell lung cancer (JCOG9304). Lung Cancer. 2004; 43:167–173.

11. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer. N Engl J Med. 2004; 350:351–362.

12. Winton TL, Livingstam R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VNR) and cisplatin (CIS) in completely resected stage Ib and II nonsmall cell lung cancer (NSCLC) Intergroup JBR 10. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22(14S):7018.

13. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage Ib nonsmall cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22(14S):7019.

14. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350:1713–1721.

15. Keicho N, Saijo N, Shinkai T, et al. Phase II study of UFT in patients with advanced nonsmall cell lung cancer. Jpn J Clin Oncol. 1986; 16:143–146.

16. Nakano J, Huang C, Liu D, et al. Evaluations of biomarkers associated with 5-FU sensitivity for nonsmall cell lung cancer patients postoperatively treated with UFT. Br J Cancer. 2006; 95:607–615.

17. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in nonsmall cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 1996; 14:1048–1054.

18. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in nonsmall cell lung cancer. J Clin Oncol. 2005; 23:4999–5006.